-
公开(公告)号：US10450377B2
公开(公告)日：2019-10-22
申请号：US15922136
申请日：2018-03-15
Applicant: Janssen Biotech, Inc.
Inventor： Karen Duffy , Natalie Fursov , LeRoy Hall , Catherine Healy , Roberta Lamb , Jinquan Luo , Ravi Malaviya , Michael Naso , Michael Pratta , Mark Tornetta , John Wheeler , Sheng-Jiun Wu
IPC: C07K16/28 , A61K39/395 , A61K38/01 , C07K16/44 , A61K39/00
Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
-
2.发明授权ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions 有权ST2L抗体拮抗剂用于治疗ST2L介导的炎症性肺病公开(公告)号：US09212227B2
公开(公告)日：2015-12-15
申请号：US13798226
申请日：2013-03-13
Applicant: Janssen Biotech, Inc.
Inventor： Karen Duffy , Natalie Fursov , LeRoy Hall , Catherine Healy , Roberta Lamb , Jinquan Luo , Ravi Malaviya , Michael Naso , Michael Pratta , Mark Tornetta , John Wheeler , Sheng-Jiun Wu
CPC classification number: C07K16/2866 , A61K38/012 , A61K39/3955 , A61K2039/505 , C07K16/44 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
Abstract translation: 本发明涉及ST2L拮抗剂，编码拮抗剂或其片段的多核苷酸，以及制备和使用上述物质的方法。
-
公开(公告)号：US20130336980A1
公开(公告)日：2013-12-19
申请号：US13798204
申请日：2013-03-13
Applicant: Janssen Biotech, Inc.
Inventor： Karen Duffy , Natalie Fursov , LeRoy Hall , Catherine Healy , Roberta Lamb , Jinquan Luo , Ravi Malaviya , Michael Naso , Michael Pratta , Mark Tornetta , John Wheeler , Sheng-Jiu Wu
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K38/012 , A61K39/3955 , A61K2039/505 , C07K16/44 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
Abstract translation: 本发明涉及ST2L拮抗剂，编码拮抗剂或其片段的多核苷酸，以及制备和使用上述物质的方法。
-
4.发明申请公开(公告)号：US20190175651A1
公开(公告)日：2019-06-13
申请号：US16215716
申请日：2018-12-11
Applicant: Janssen Biotech, Inc.
Inventor： John Lee , Jill Mooney , Michael Naso
IPC: A61K35/17 , C07K14/78 , C07K14/47 , C07K14/705 , C07K14/715 , A61P35/00 , C12N15/85 , C12N15/90
Abstract: The present invention pertains to engineered immortalized T-cell lines, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immortalized T-cell lines of the invention are characterized in that the expression of endogenous T-cell receptors (TCRs) and beta 2-microglobulin (B2M) is inhibited, e.g., by using an endonuclease able to selectively inactivate the TCR and B2M genes in order to render the immortalized T-cells non-alloreactive. In addition, expression of immunosuppressive polypeptide can be performed on those engineered immortalized T-cells in order to prolong the survival of these T-cells in host organisms. Such engineered immortalized T-cells are particularly suitable for allogeneic transplantations, especially because it reduces both the risk of rejection by the host's immune system and the risk of developing graft versus host disease. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immortalized T-cells for treating cancer, infections and auto-immune diseases.
-
公开(公告)号：US20180243416A1
公开(公告)日：2018-08-30
申请号：US15906887
申请日：2018-02-27
Inventor： Maria P. Limberis , Anna P. Tretiakova , James M. Wilson , Michael Naso , Joost Kolkman , Robert Friesen , Qiang Wang
IPC: A61K39/42 , C12N7/06 , A61K39/145 , A61P31/16
Abstract: A non-replicating recombinant adeno-associated associated virus (rAAV) having an AAV capsid having packaged therein a vector genome which comprises AAV inverted terminal repeat sequences and at least one nucleic acid sequence encoding four different immunoglobulin regions (a), (b), (c) and (d) is provided. The rAAV-expressed immunoglobulins are useful for providing passive immunization against influenza A and influenza B. Also described herein are compositions containing the rAAV. Methods of vaccinating patients against influenza are provided.
-
Patent Agency Ranking
公开(公告)号：US20160194405A1
公开(公告)日：2016-07-07
申请号：US14992519
申请日：2016-01-11
Applicant: Janssen Biotech, Inc.
Inventor： G. Mark Anderson , Bernard Scallon , Michael Naso , Ann Cai , Cam Holland
IPC: C07K16/36 , A61K31/4164 , A61K51/00 , A61K47/48 , A61K9/00 , C07K16/30 , A61K39/395
CPC classification number: C07K16/36 , A61K9/0019 , A61K31/4164 , A61K39/3955 , A61K47/6849 , A61K51/00 , A61K2039/505 , A61K2039/507 , C07K16/30 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3069 , C07K2317/24 , C07K2317/52 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.
-
公开(公告)号：US20140057319A1
公开(公告)日：2014-02-27
申请号：US13974655
申请日：2013-08-23
Applicant: Janssen Biotech, Inc.
Inventor： Michael Naso , T.Shantha Raju , Bernard Scallon
IPC: C07K16/24
CPC classification number: C12N9/2402 , C07K16/00 , C07K16/241 , C07K2317/41 , C07K2317/72 , C07K2317/732 , C12N15/85 , C12P21/005 , C12Y302/01018
Abstract: The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the FcγRI, FcγRIIA, and FcγRIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.
Abstract translation: 通过用编码唾液酸酶的载体序列转染表达含Fc的蛋白质的细胞系，通过改变Fc区中寡糖的唾液酸化来控制含Fc的蛋白质，例如抗体的性质。 经修饰的含Fc蛋白质具有治疗效用，其中希望控制对FcγRα，FcγRIIA和FcγRIIIA受体的一种或多种的亲和力，ADCC活性，巨噬细胞或单核细胞活化，血清半衰期和 亲和力
-
8.发明授权公开(公告)号：US11161897B2
公开(公告)日：2021-11-02
申请号：US16037340
申请日：2018-07-17
Applicant: Janssen Biotech, Inc.
Inventor： Chichi Huang , John Lee , Jill Mooney , Michael Naso
IPC: C07K16/28 , C07K16/46 , C07K14/735 , A61K39/395 , C07K16/18
Abstract: Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.
-
9.发明授权公开(公告)号：US11096998B2
公开(公告)日：2021-08-24
申请号：US16323121
申请日：2017-09-11
Applicant: Janssen Biotech, Inc.
Inventor： Chen Ni Chin , John Lee , Timothy McCabe , Jill Mooney , Michael Naso , William Strohl
IPC: C07K16/00 , C07K16/46 , C07K16/28 , A61K39/00 , C12N15/82 , A61P35/00 , C07K14/525 , C07K14/705 , C07K14/75 , C07K14/78
Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
-
10.发明申请公开(公告)号：US20190330361A1
公开(公告)日：2019-10-31
申请号：US16323121
申请日：2017-09-11
Applicant: Janssen Biotech, Inc.
Inventor： Chen Ni Chin , John Lee , Timothy McCabe , Jill Mooney , Michael Naso , William Strohl
Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.022 seconds)
